Cogentix Medical (CGNT) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cogentix Medical Reports 83% Second Quarter Revenue Growth
November 3, 2015 4:01 PM ESTMINNEAPOLIS, Nov. 3, 2015 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced results for the fiscal second quarter ended September 30, 2015.
Second Quarter Fiscal 2016 Overview
Revenue of $11.8 million increased 83% from $6.5 million reported in the year-ago period (86% on a constant currency basis) Revenue of $11.8 million increased 12% from the pro forma combined revenue of Uroplasty and Vision-Sciences in the same period last year (14% on a constant currency basis) U.S.... More